Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: An analysis of national health and nutritional examination survey data, 2001-2010

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Kuznik, Andreas ^a   Mardekian, Jack ^a   Tarasenko, Lisa ^a  

^a PFIZER INC   (United States)

Author keywords

Blood Pressure; Cardiovascular Risk Factors; Chronic Kidney Disease; Goal Attainment; Low density Lipoprotein Cholesterol

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE CONTROL; FEMALE; GLOMERULUS FILTRATION RATE; GOAL ATTAINMENT; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; SELF REPORT; SENSITIVITY ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ADULT; CARDIOVASCULAR DISEASES; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; GOALS; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; UNITED STATES;

EID: 84879451349     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-132     Document Type: Article

References (48)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation, Am J Kidney Dis 2002 39 2 Suppl 1 1 S266 11904577
2. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Disease, Kidney Int Suppl 2013 3 1 1 150
3. Prevalence of chronic kidney disease in the United States. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS, JAMA 2007 298 17 2038 2047 10.1001/jama.298.17.2038 17986697
4. Cardiovascular disease and chronic renal disease: a new paradigm. Sarnak MJ, Levey AS, Am J Kidney Dis 2000 35 4 Suppl 1 117 S131 10766010
5. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, Circulation 2003 108 17 2154 2169 10.1161/01.CIR.0000095676.90936.80 14581387
6. Chronic kidney disease and mortality risk: a systematic review. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX, J Am Soc Nephrol 2006 17 7 2034 2047 10.1681/ASN.2005101085 16738019
7. Chronic kidney disease and cardiovascular disease in the Medicare population. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA, Kidney Int 2003 64 Suppl 87 24 S31
8. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 13 1296 1305 10.1056/NEJMoa041031 15385656
9. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH, Arch Intern Med 2004 164 6 659 663 10.1001/archinte.164.6.659 15037495
10. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National kidney foundation task force on cardiovascular disease. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr, Am J Kidney Dis 1998 32 5 853 906 10.1016/S0272-6386(98)70145-3 9820460
11. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 41 4 Suppl 3 1 S91 12751048
12. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2004 43 5 Suppl 1 1 S290 15114537
13. Hyperlipidemia in patients with chronic renal disease. Kasiske BL, Am J Kidney Dis 1998 32 5 Suppl 3 142 S156 9892381
14. Hypertension in patients with chronic renal disease. Mailloux LU, Levey AS, Am J Kidney Dis 1998 32 5 Suppl 3 120 S141 9820471
15. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M, Circulation 2004 110 12 1557 1563 10.1161/01.CIR.0000143892.84582.60 15364796
16. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the treating to new targets (TNT) study. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators, J Am Coll Cardiol 2008 51 15 1448 1454 10.1016/j.jacc.2007.11.072 18402899
17. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators, Am J Kidney Dis 2009 53 5 741 750 10.1053/j.ajkd.2008.11.025 19216014
18. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial. Ridker PM, MacFadyen J, Cressman M, Glynn RJ, J Am Coll Cardiol 2010 55 12 1266 1273 10.1016/j.jacc.2010.01.020 20206456
19. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, Elam JT, Applegate WB, Arch Intern Med 1998 158 12 1340 1345 10.1001/archinte.158.12.1340 9645829
20. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S, Ann Intern Med 2001 134 8 629 636 10.7326/0003-4819-134-8- 200104170-00007 11304102
21. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC, Circulation 2005 112 2 171 178 10.1161/CIRCULATIONAHA.104.517565 15998677
22. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators, CJASN 2007 2 6 1131 1139 17942759
23. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD, Clin Ther 2011 33 6 717 725 10.1016/j.clinthera.2011.05.004 21704236
24. National Health and Nutrition Examination Survey, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), About the National Health and Nutrition Examination Survey, 2001-2010 http://www.cdc.gov/nchs/nhanes/about-nhanes.htm 23808993
25. National Health and Nutrition Examination Survey, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Health and Nutrition Examination Survey questionnaires, datasets, and related documentation, 2001-2010 http://www.cdc.gov/nchs/nhanes/nhanes- questionnaires.htm
26. A new equation to estimate glomerular filtration rate. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ann Intern Med 2009 150 9 604 612 10.7326/0003-4819-150-9-200905050-00006 19414839
27. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, JAMA 2001 285 19 2486 2497 10.1001/jama.285.19.2486 11368702
28. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program, Circulation 2004 110 2 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
29. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the national heart, lung, and blood institute. American Heart Association, American College of Cardiology, Circulation 2006 113 19 2363 2372 10.1161/CIRCULATIONAHA. 106.174516 16702489
30. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2007 49 2 Suppl 2 12 S154 17276798
31. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators, N Engl J Med 2005 353 3 238 248 10.1056/NEJMoa043545 16034009
32. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group, N Engl J Med 2009 360 14 1395 1407 10.1056/NEJMoa0810177 19332456
33. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators, Lancet 2003 361 9374 2024 2031 10.1016/S0140-6736(03)13638-0 12814712
34. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC, BMJ 2008 336 7645 645 651 10.1136/bmj.39472.580984.AE 18299289
35. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF, Cochrane Database Syst Rev 2009 2 D007784 10.1002/14651858.CD007784
36. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G, Ann Intern Med 2003 138 2 98 104 10.7326/0003-4819-138-2-200301210- 00010 12529091
37. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The SHARP Collaborative Group, Lancet 2011 377 9784 2181 2192 10.1016/S0140-6736(11)60739-3 21663949
38. Treatment blood pressure targets for hypertension. Arguedas JA, Perez MI, Wright JM, Cochrane Database Syst Rev 2009 3 CD004349 10.1002/14651858. CD004349.pub2
39. Risk implications of the new CKD epidemiology collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the atherosclerosis risk in communities (ARIC) study. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J, Am J Kidney Dis 2010 55 4 648 659 10.1053/j.ajkd.2009. 12.016 20189275
40. Comparison of the CKD epidemiology collaboration (CKD-EPI) and modification of diet in renal disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the kidney early evaluation program (KEEP). Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA, Am J Kidney Dis 2011 57 3 Suppl 2 9 S16 21338849
41. US Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2012
42. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G, Kidney Int 2005 67 6 2089 2100 10.1111/j.1523-1755.2005. 00365.x 15882252
43. Definition and classification of CKD: the debate should be about patient prognosis. A position statement from KDOQI and KDIGO. Eckardt KU, Berns JS, Rocco MV, Kasiske BL, Am J Kidney Dis 2009 53 6 915 920 10.1053/j.ajkd.2009.04. 001 19406541
44. The KDOQI 2002 classification of chronic kidney disease: for whom the bell tolls. Hallan SI, Orth SR, Nephrol Dial Transplant 2010 25 9 2832 2836 10.1093/ndt/gfq370 20601368
45. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, Nephrol Dial Transplant 2008 23 12 3851 3858 10.1093/ndt/gfn356 18641082
46. US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2010
47. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB, J Am Soc Nephrol 2004 15 5 1300 1306 10.1097/01.ASN.0000125670.64996. BB 15100370
48. A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy. Menzin J, Lines LM, Weiner DE, Neumann PJ, Nichols C, Rodriguez L, Agodoa I, Mayne T, PharmacoEconomics 2011 29 10 839 861 10.2165/11588390-000000000-00000 21671688